Seite 1 von 2
Neuester Beitrag: 24.04.21 23:12
|Eröffnet am:||05.06.13 11:24||von: Forscher||Anzahl Beiträge:||30|
|Neuester Beitrag:||24.04.21 23:12||von: Franziskaxm.||Leser gesamt:||9.324|
|Seite: < 1 | 2 >|
With just a quick glance at a chart of Easton Pharmaceuticals Inc. (OTCMKTS:EAPH), it may appear as if the stock was still spinning wheels, drifting listlessly between $0.005 and $0.012. The longer you look at a chart of EAPH, however, the more you have to wonder if a bullish paradigm shift is underway.
For those not familiar with the company, EAPH is a biopharma name. Its claim to fame is small but well-received library of topical treatments for everything from sexual dysfunction to stretch marks to varicose veins... creams and ointments created when the company was operating under the moniker LAM Industries. Its name was changed in 2010 to Easton Pharmaceuticals, though technically speaking, it doesn't have any actual FDA-approved, internally-administered drugs in its portfolio.... or didn't, anyway. The company is wading back into drug waters, taking the medical marijuana route.
Biotech trading veterans will know how big of a deal that could be for Easton Pharmaceuticals and EAPH shareholders. The advent of legalized marijuana - mostly for medicinal purposes, but also for recreational uses in some states - has put hemp and marijuana stocks at center stage for nearly a year now, and has been very good for those related stocks. EAPH didn't participate in most of that euphoria, as it only announced it was developing a medical marijuana product until early June, and didn't offer any real details of its plans until late August.
The timing and news are academic at this point, however. What matters most now, to us, are the bullish hints the chart is dropping... they're pointing to more upside.
Since early August when Easton Pharmaceuticals put itself back on the map by announcing it was getting into the medical marijuana race, we've seen a string of higher lows; we're also working higher highs (we've already made one higher high). At the same time, the volume the stock's been producing since the news made the company 'real' is noticeable better than the volume we were seeing before the news. Finally, Easton Pharmaceuticals is now finding support at its key long-term moving average lines like the 100-day line (gray) and the 200-day moving average line (green).
It admittedly doesn't seem like much to go on, but often, the subtle clues are the best ones. EAPH is slowly but surely on the mend. In fact, it's already mended - now it's just firming up its foundation from which it can stage an even bigger rally. It may not seem like much right now, but Easton Pharmaceuticals is setting itself up to be one of Q4's better Cinderella stories.
October 22, 2013, 8:06 a.m. ET Easton Pharmaceuticals Announces Formal Agreement & Advances Payment to BMV Medica S.A. Towards a Regulatory Filing in Mexico for "Viorra"; Company Anticipates Approval and Initial Sales by End of Second Quarter 2014.